How to Catch Risky Claims Before a Pharma Campaign Launches
How to catch risky pharma claims before launch: claim libraries, common risk patterns, pre-review checks, AI-assisted screening, and live QA.
The short answer
Risky claims are caught before launch through layers: a claims library of approved statements with references, a pre-review checklist that flags common risk patterns such as overstated efficacy, missing risk information, implied off-label uses, and unsupported comparisons, careful review of how claims appear in each format, and final QA of live placements. AI tools can help screen drafts, but human reviewers make the decisions.
Most promotional problems are predictable. The same patterns show up in FDA letters year after year. Catching them before review saves rounds; catching them before launch prevents letters.
Common risk patterns
| Pattern | Example of the risk |
|---|---|
| Overstated efficacy | "Clears skin" when data shows improvement for some patients |
| Minimized risk | Risk information too small, too fast, or buried |
| Omitted material facts | Leaving out limitations of use or important warnings |
| Implied off-label use | Imagery or audience suggesting an unapproved population |
| Unsupported comparison | "Better than" without head-to-head data |
| Misleading data presentation | Relative risk without absolute numbers, truncated charts |
| Overstated convenience | Implying no monitoring when monitoring is required |
FDA publishes untitled and warning letters. Reading them by category builds an instinct for these patterns. See OPDP letters: lessons for media teams.
Layer 1: Claims library
Keep approved claims with references, approval dates, and allowed contexts. Writers start from the library, not from scratch. New claims go through full review before entering the library.
Layer 2: Pre-review checklist
Before submission, the brand or agency checks:
- Every claim is in the library or flagged as new.
- Each claim has a reference.
- Risk information is present and proportionate in this format.
- Images and audience do not imply off-label use.
- Comparisons have adequate support.
- Data visuals are not distorted.
Layer 3: Format-specific review
The same claim can be fine in a brochure and risky in a 6-second video. Review each format as viewers will see it:
- Small display units.
- Social posts and comment threads.
- Search ads with character limits.
- Dynamic creative combinations. See dynamic creative rules.
- CTV with risk presentation timing.
Layer 4: AI-assisted screening
AI tools can flag likely issues: missing risk statements, superlatives, claims not in the library. Use them as a first pass. They miss context and can produce false confidence. Keep human reviewers accountable. See human review for AI-assisted marketing.
Layer 5: Live QA
Check what actually runs:
- Screenshots of live placements.
- Correct version and approval number.
- Working links to prescribing information.
- Expiry dates honored.
Common mistakes
- Reviewing static mockups for dynamic formats.
- Approving claims without context rules.
- Assuming an AI check equals review.
- No live QA after launch.
Practical takeaway
Collect the last ten review rejections your brand received and group them by risk pattern. The top two patterns are where a pre-review checklist will save the most time.
Frequently asked questions
What are the most common risky claims in pharma ads?
Overstated efficacy, minimized or missing risk information, implied uses beyond the label, unsupported superiority, and misleading presentation of data.
Can AI review pharma claims?
AI can help flag likely issues and check references, but final judgment belongs to qualified human reviewers.
How do you catch claim problems in dynamic ads?
Approve the full set of possible combinations, lock rules that prevent unapproved assembly, and test live outputs.
Sources
- FDA, Untitled Letters
- FDA, Warning Letters and Notice of Violation Letters to Pharmaceutical Companies
- FDA, Presenting Risk Information in Prescription Drug and Medical Device Promotion
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.